Omnicell (NSDQ:OMCL) and Fresenius Kabi announced today that they are collaborating on new technology for managing controlled substances.
The collaboration aims to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing controlled substances in patient care areas.
Get the full story at our sister site, Drug Delivery Business News.